Humacyte, Inc.
- Last sale
- Nov 12, 2026 · +0.34%
- Market cap
- $165.54M
- 277.8M shares
- Filings
- 506
Q3 2026
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+12.4% FY25 yoy
- $165.54M
- —
- 69.1×
- 9.2×
- -53.51%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2,038,000 | reported | |
| FY 2024 | 2024-12-31 | $0 | reported |
Segments
Products
LineFY2025ShareChange
Product$1.39M68%—
Contract Revenue$649.00K32%—
Total$2.04M
Biological products, except diagnostic substances
Humacyte, Inc. is the 75th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
CGONCG Oncology, Inc.$4.0M254.7%3,985.0%$6.8BCRSPCRISPR Therapeutics AG$3.5M90.6%16,569.8%$4.1BSRZNSurrozen, Inc.$3.5M67.4%6,960.8%$605.8MDYAIDyadic International Inc$3.1M11.6%238.3%$13.3MALGSAligos Therapeutics, Inc.$2.2M39.5%1,106.7%$12.6M
HUMAHumacyte, Inc. (this company)$2.0M—2,003.6%$165.5M
OTLKOutlook Therapeutics, Inc.$1.4M—4,416.2%$107.1MSCNIScinai Immunotherapeutics Ltd.$1.3M99.2%633.6%$1.6MINBXInhibrx Biosciences, Inc.$1.3M550.0%10,773.5%$1.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Humacyte, Inc. · CIK 1818382 · Engraved from SEC EDGAR